SEDAR Interim Financial Statements

[
  {
    "companyName": "Telo Genomics Corp.",
    "reportingPeriodEnd": "2025-12-31",
    "reportStatus": "Unaudited",
    "auditorName": null,
    "auditorKeyMatters": [],
    "balanceSheet": {
      "cash": 50110,
      "amountsReceivable": 14987,
      "prepaidExpenses": 51355,
      "totalCurrentAssets": 116452,
      "propertyAndEquipment": 32285,
      "rightOfUseAsset": 189055,
      "intangibleAsset": 0,
      "totalNonCurrentAssets": 221340,
      "totalAssets": 337792,
      "accountsPayableAndAccruedLiabilities": 729812,
      "leaseLiabilitiesCurrent": 77850,
      "totalCurrentLiabilities": 807662,
      "leaseLiabilitiesNonCurrent": 83455,
      "totalLiabilities": 891117,
      "shareCapital": 24624595,
      "sharesToBeIssued": 0,
      "contributedSurplus": 6440366,
      "deficit": -31618286,
      "totalEquity": -553325,
      "cashPerShare": 0.0005,
      "workingCapitalPerShare": -0.0069
    },
    "incomeStatement": {
      "generalAndAdministrative": 509101,
      "researchAndDevelopment": 559205,
      "totalExpenses": 1068306,
      "grantSubsidy": 0,
      "netLoss": 1068306,
      "basicAndDilutedLossPerShare": -0.01,
      "weightedAverageSharesOutstanding": 100408106
    },
    "cashFlowStatement": {
      "netLoss": 1068306,
      "depreciationOfPropertyAndEquipment": 22691,
      "shareBasedCompensation": 0,
      "changeInAmountsReceivable": 11552,
      "changeInPrepaidExpenses": 25075,
      "changeInAccountsPayableAndAccruedLiabilities": 333493,
      "changeInLeaseLiabilities": 161305,
      "cashUsedInOperatingActivities": -514190,
      "labEquipmentAdditions": -16676,
      "rightOfUseAssetAdditions": -206242,
      "additionsToPropertyAndEquipment": -2075,
      "cashFlowsUsedInInvestingActivities": -224993,
      "proceedsFromIssuanceOfCommonShares": 0,
      "findersFeesCash": 0,
      "shareIssuanceCosts": 0,
      "cashFlowsFromFinancingActivities": 0,
      "changeInCash": -739183,
      "cashBeginningOfYear": 789293,
      "cashEndOfPeriod": 50110
    },
    "investmentsAndOtherAssets": [
      {
        "type": "Subsidiary",
        "description": "Telo Genomics Holdings Corp., a wholly owned subsidiary",
        "ownershipPercentage": 100,
        "value": null,
        "notes": "Incorporated under the Canadian Business Corporations Act"
      },
      {
        "type": "Intangible Asset",
        "description": "Exclusive license to commercialize diagnostic and prognostic test products",
        "ownershipPercentage": null,
        "value": 0,
        "notes": "Repurchased from Knight Therapeutics Inc. on April 27, 2020. Written down to $0 as of June 30, 2025."
      }
    ],
    "shareStructure": {
      "authorizedShares": "unlimited",
      "issuedShares": 100430472,
      "classesOfShares": ["common voting shares", "non-voting common shares", "Class A shares", "Class B shares", "Class C shares", "Class D shares"],
      "warrants": [
        {
          "number": 1625000,
          "exercisePrice": 0.4,
          "expiryDate": "2027-06-21"
        },
        {
          "number": 25459000,
          "exercisePrice": 0.15,
          "expiryDate": "2027-12-23"
        }
      ],
      "options": [
        {
          "number": 60000,
          "exercisePrice": 0.15,
          "expiryDate": "2026-03-06"
        },
        {
          "number": 100000,
          "exercisePrice": 0.64,
          "expiryDate": "2026-04-01"
        },
        {
          "number": 121924,
          "exercisePrice": 10.15,
          "expiryDate": "2026-09-26"
        },
        {
          "number": 20000,
          "exercisePrice": 2.2,
          "expiryDate": "2026-10-27"
        },
        {
          "number": 50625,
          "exercisePrice": 2.85,
          "expiryDate": "2027-01-18"
        },
        {
          "number": 250000,
          "exercisePrice": 0.335,
          "expiryDate": "2027-03-15"
        },
        {
          "number": 10000,
          "exercisePrice": 0.34,
          "expiryDate": "2027-07-18"
        },
        {
          "number": 175000,
          "exercisePrice": 0.265,
          "expiryDate": "2027-09-30"
        },
        {
          "number": 250000,
          "exercisePrice": 0.15,
          "expiryDate": "2028-03-06"
        },
        {
          "number": 200000,
          "exercisePrice": 0.2,
          "expiryDate": "2028-12-08"
        },
        {
          "number": 1800000,
          "exercisePrice": 0.15,
          "expiryDate": "2030-03-06"
        },
        {
          "number": 850000,
          "exercisePrice": 0.15,
          "expiryDate": "2030-04-01"
        }
      ],
      "rightsConvertibleInstruments": null
    },
    "managementCompensation": {
      "currency": "CAD",
      "periods": {
        "2025-12-31": {
          "salariesFeesAndShortTermBenefits": 151124,
          "shareBasedCompensation": 0,
          "total": 151124
        },
        "2024-12-31": {
          "salariesFeesAndShortTermBenefits": 215397,
          "shareBasedCompensation": 0,
          "total": 215397
        }
      },
      "namedIndividuals": [],
      "otherRelatedPartyTransactions": []
    },
    "subsequentEvents": [
      {
        "eventDate": null,
        "description": "550,000 stock options expired unexercised.",
        "impactValue": null
      },
      {
        "eventDate": null,
        "description": "Closed first tranche of non-transferable secured convertible debentures for gross proceeds of $840,000, issuing 16,800,000 warrants at $0.08 expiring February 17, 2027 and 1,176,000 finder's warrants at $0.08 expiring February 17, 2028.",
        "impactValue": 840000
      }
    ]
  }
]